PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Disease Reportsthromboembolism
MeSH D013923 - thromboembolism
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
See list view
D016769:Embolism and thrombosis
0 Companies
0 Drugs
Success rate
D013923: 
Thromboembolism
54 Companies
14 Drugs
$
Success rate
D002542:Intracranial embolism and thrombosis
8 Companies
2 Drugs
$
Success rate
D019320:Paradoxical embolism
0 Companies
0 Drugs
Success rate
D054556:Venous thromboembolism
8 Companies
5 Drugs
$
Success rate
Events Timeline
Loading
Commercial
Company Name
Drug Name
Trade Name
Patent Expires
Approval Date
Revenue
Period
Taro PharmaceuticalWarfarin Warfarin  1999-07-15   
LEO PharmaTinzaparin Innohep  2000-07-14   
MylanHeparin Heparin  2017-11-30   
CiplaWarfarin Warfarin  2011-05-25   
SandozEnoxaparin Enoxaparin  2010-07-23   
Heparin Heparin  2011-06-08   
OrganonHeparin Liquaemin  1982-01-01   
Phenprocoumon Liquamar  1982-01-01   
NovartisHeparin, Lidocaine, Dihydroergotamine Embolex  1984-11-30   
SanofiHeparin Calciparine  1982-01-01   
Enoxaparin Lovenox  1993-03-29   
1
2
3
4
5
6
>
Clinical Trials
Historical Success Rate
Phase 1
25%
1/4
Phase 2
48%
13/27
Phase 3
77%
20/26
Approved: 11Overall Success rate: 9%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name
Phase 1
Phase 2
Phase 3
Phase 4
Drug Name
LEO Pharma
Tinzaparin,
Tinzaparin sodium
Organon
Heparin,
Heparin sodium,
Antithrombin iii,
Serine
Novartis
Dihydroergotamine,
Heparin,
Heparin sodium,
Lidocaine
Sanofi
Heparin,
Enoxaparin sodium,
Enoxaparin,
Heparin sodium,
Antithrombin iii,
Serine
Pfizer
Heparin,
Dalteparin,
Heparin sodium,
Dalteparin sodium,
Antithrombin iii,
Serine
Eli Lilly
Heparin,
Heparin sodium
1
2
3
4
>
© 2020-2023 Collaborative Drug Discovery Inc. (CDD) | Terms of Use